ClinicalTrials.Veeva

Menu

Serum Soluble BCMA as a Non-Invasive Marker in Multiple Myeloma

A

Assiut University

Status

Not yet enrolling

Conditions

Multiple Myeloma

Study type

Observational

Funder types

Other

Identifiers

NCT07855718
sBCMA-MM-Assiut-2026

Details and patient eligibility

About

This prospective study aims to investigate serum soluble B-cell maturation antigen (sBCMA) as a non-invasive marker in patients with multiple myeloma and to compare its levels with healthy controls.

Full description

Multiple myeloma is a malignant plasma cell disorder. Current monitoring relies on invasive bone marrow examination and monoclonal protein assays, which may be limited in oligosecretory disease.

This observational study will measure serum soluble BCMA levels in newly diagnosed and relapsed/refractory multiple myeloma patients and compare them with healthy controls. The relationship between sBCMA levels and clinical and laboratory disease characteristics will be assessed.

Enrollment

90 estimated patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Group 1 (Newly Diagnosed MM):
  • Age 18 years or older
  • Newly diagnosed multiple myeloma according to WHO 2022 criteria
  • Pretreatment at time of sample collection

Group 2 (Relapsed/Refractory MM):

  • Age 18 years or older
  • Confirmed multiple myeloma with documented relapse or refractory disease after at least one prior line of therapy

Group 3 (Controls):

  • Age 18 years or older
  • Healthy volunteers with normal CBC and renal function
  • Age and sex matched to patient groups

Exclusion criteria

  • - Other active malignancies or autoimmune diseases
  • Severe renal impairment (serum creatinine > 3.0 mg/dL)
  • Active infection or inflammatory disease at sampling
  • Pregnancy or lactation

Trial design

90 participants in 3 patient groups

Newly Diagnosed Multiple Myeloma
Description:
Patients with newly diagnosed multiple myeloma before initiation of treatment.
Relapsed/Refractory Multiple Myeloma
Description:
Patients with relapsed or refractory multiple myeloma after at least one prior line of therapy.
Healthy Controls
Description:
Age- and sex-matched healthy volunteers with normal CBC and renal function.

Trial contacts and locations

0

Loading...

Central trial contact

Naira A Ezz, Resident

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems